Researchers at Emory University conducted qualitative interviews with 24 women with FXPOI exploring how FMR1 screening, physician education, and supportive care impacted their experience receiving a diagnosis. Their results are in!
Highlighting the Fragile X Clinic at Stanford University School of Medicine in California, a member of the National Fragile X Foundation’s Fragile X Clinical & Research Consortium (FXCRC)
Tetra Therapeutics Shares Details of the Now Enrolling FXS Trials in a Short Video.
NFXF Western Massachusetts and Connecticut chapters host a night out
Jaleesa Holden, NFXF Communications Manager, shares her experience as a first-time advocate at NFXF Advocacy Day 2023.
Zynerba Pharmaceuticals shares why the RECONNECT trial with ZYN002 is being conducted in Fragile X syndrome
We asked our 2022 NFXF-funded Randi J Hagerman Summer Scholars to summarize their summer project in a 15-minute video presentation, and here they are!
NFXF Advocates head to Capitol Hill to ask for ongoing federal funding for Fragile X research and legislation to support telemedicine
Announcing FY 2023 federal research funding opportunities across six award categories available for all Fragile X- associated conditions and disorders.
Executive Director Hilary Rosselot welcomes the incoming class of 2023 Board Members. We look forward to working together to serve the entire Fragile X community.
Announcing a new Fragile X clinic located at Children's Hospital Philadelphia
Help the NFXF and FXAA- share your opinion of common Fragile X premutation terminology by completing this quick survey.
Dr. Randi Hagerman discusses all of the Fragile X-associated conditions and disorders and provides strategies for some of their characteristics.
Announcing a new Fragile X clinic located at Children's Hospital New Orleans which will serve the Greater Gulf South region
On this Giving Tuesday, we want to give you a gift of thanks - and one we believe will help you on your own Fragile X journey.
